#### **SQUINTO STEPHEN P**

Form 4 April 04, 2007

## FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

**OMB** 3235-0287 Number:

Check this box if no longer subject to

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES** 

January 31, Expires: 2005

0.5

**OMB APPROVAL** 

Section 16. Form 4 or Form 5 obligations

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

2. Issuer Name and Ticker or Trading

burden hours per response...

5. Relationship of Reporting Person(s) to

Issuer

Estimated average

See Instruction

may continue. 30(h) of the Investment Company Act of 1940

1(b).

share

(Print or Type Responses)

SOUINTO STEPHEN P

1. Name and Address of Reporting Person \*

SQUINTO STEPHEN P			Symbol ALEXION PHARMACEUTICALS INC [ALXN]					(Check all applicable)				
(Last) (First) (Middle)  C/O ALEXION PHARMACEUTICALS INC, 352 KNOTTER DRIVE			3. Date of Earliest Transaction (Month/Day/Year) 04/03/2007					Director 10% Owner Officer (give title Other (specify below) below)  EVP & Head of Research				
				4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting			
	CHESHIRE,	, CT 06410							Person	Tore than one re	porting	
	(City)	(State)	(Zip)	Tabl	e I - Non-D	<b>Derivative</b>	Secur	ities Acq	uired, Disposed o	f, or Beneficial	ly Owned	
	1.Title of Security (Instr. 3)	2. Transaction Da (Month/Day/Yea	r) Execution	emed on Date, if /Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired n(A) or Disposed of (D) (Instr. 3, 4 and 5)  (A) or		Owned Indirect (I) Own Following (Instr. 4) (Instream Reported Transaction(s)				
	_				Code V	Amount		Price	(Instr. 3 and 4)			
	Common Stock, par value \$.0001 per share	04/03/2007			M	9,500	A	\$ 10.5	25,014	D		
	Common Stock, par value \$.0001 per	04/03/2007			S	2,786 (1)	D	\$ 43.52	22,228	D		

#### Edgar Filing: SQUINTO STEPHEN P - Form 4

Common Stock, par value \$.0001 per share	04/03/2007	S	300	D	\$ 43.57 21,928	D
Common Stock, par value \$.0001 per share	04/03/2007	S	518	D	\$ 43.6 21,410	D
Common Stock, par value \$.0001 per share	04/03/2007	S	5,896	D	\$ 15,514 43.55	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number	6. Date Exerci	sable and	7. Title and A	Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transaction Derivative		Expiration Date		Underlying Securities	
Security	or Exercise		any	Code Securities		(Month/Day/Year)		(Instr. 3 and 4)	
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Acquired				
	Derivative				(A) or				
	Security			Disposed of					
				(D)					
				(Instr. 3, 4,					
					and 5)				
						Date	Expiration	Title	Amount or Number
				Code V	(A) (D)	Exercisable	Date	1100	of Shares
Option to Purchase Common Stock	\$ 10.5	04/03/2007		M	9,500	07/31/2000	07/31/2007	Common Stock, par value \$.0001	9,500
								per share	

# **Reporting Owners**

Reporting Owner Name / Address		Keiationsnips					
	Director	10% Owner	Officer	Other			

Reporting Owners 2

SQUINTO STEPHEN P C/O ALEXION PHARMACEUTICALS INC 352 KNOTTER DRIVE CHESHIRE, CT 06410

EVP & Head of Research

### **Signatures**

/s/ Stephen 04/04/2007 Squinto

\*\*Signature of Date
Reporting Person

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sales reported by this Form 4 are made pursuant to the terms of a Sales Plan designed to meet the requirements of Rule 10b5-1 (c) (1) of the Securities Exchange Act.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3